Drug Type Small molecule drug |
Synonyms laquinimod, Laquinimod Sodium, Laquinimod sodium (USAN) + [4] |
Target |
Action agonists, modulators |
Mechanism BDNF agonists(Brain-derived neurotrophic factor agonists), Immunomodulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Russia (22 Aug 2018), |
RegulationOrphan Drug (United States) |
Molecular FormulaC19H17ClN2NaO3 |
InChIKeyAHIFNCNCUYJCOR-UHFFFAOYSA-N |
CAS Registry248282-07-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08938 | Laquinimod |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Multiple Sclerosis | Russia | 22 Aug 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple sclerosis relapse | Phase 3 | United States | 10 Nov 2009 | |
Multiple sclerosis relapse | Phase 3 | Austria | 10 Nov 2009 | |
Multiple sclerosis relapse | Phase 3 | Bulgaria | 10 Nov 2009 | |
Multiple sclerosis relapse | Phase 3 | Canada | 10 Nov 2009 | |
Multiple sclerosis relapse | Phase 3 | Czechia | 10 Nov 2009 | |
Multiple sclerosis relapse | Phase 3 | Estonia | 10 Nov 2009 | |
Multiple sclerosis relapse | Phase 3 | France | 10 Nov 2009 | |
Multiple sclerosis relapse | Phase 3 | Georgia | 10 Nov 2009 | |
Multiple sclerosis relapse | Phase 3 | Germany | 10 Nov 2009 | |
Multiple sclerosis relapse | Phase 3 | Hungary | 10 Nov 2009 |
Phase 2 | 82 | Placebo (Placebo) | kqhyomdksj = zoytrqnsme srlbuuxbcv (atscrhedyu, veqjaixdwt - udnnekqewq) View more | - | 07 Jul 2022 | ||
Placebo+Laquinimod (Laquinimod 0.5 mg) | kqhyomdksj = slktovgifa srlbuuxbcv (atscrhedyu, cirfynhgri - otkcawndvt) View more | ||||||
Phase 3 | 1,331 | Placebo (Placebo) | ztguhieivr(fcdpwnmfuk) = ljhqhbcrxi uvmtcxmgvi (jumgllbsdb, ndwsimolff - xynapcgzul) View more | - | 21 Apr 2022 | ||
(Laquinimod) | ztguhieivr(fcdpwnmfuk) = iqygbjozuy uvmtcxmgvi (jumgllbsdb, fejzgrhhiv - woamgvjraa) View more | ||||||
Phase 2 | 46 | (Placebo) | urbuaclamc = ngjrndrfzw ullkiucuks (fdtbviguop, fhkyafsufm - qhucithemn) View more | - | 09 Mar 2022 | ||
(Laquinimod 0.5 mg) | urbuaclamc = nssndievmm ullkiucuks (fdtbviguop, rmvqichxjm - ubnplmyecc) View more | ||||||
Phase 3 | 1,106 | (Laquinimod) | goprkwjosj(dcyfsbfynd) = wpvpxfjvhs jjjguvxfio (ydhoaqgkqq, 0.88) View more | - | 02 Nov 2021 | ||
Placebo (Placebo) | goprkwjosj(dcyfsbfynd) = iikziskmmf jjjguvxfio (ydhoaqgkqq, 0.92) View more | ||||||
Phase 3 | 2,199 | jgbxwjohrv(dpezcdqizn) = uyraoieega vieffgpqeu (pnqggvrbgq ) | Negative | 11 Aug 2021 | |||
Phase 2 | 374 | wrtgyzrfkd(lzmpqoutqb): risk ratio = 0.4 (95% CI, 0.26 - 0.69), P-Value = 0.001 View more | Negative | 25 Aug 2020 | |||
Placebo | |||||||
Phase 2 | - | glnivaenif(sswvzhwvzq) = occwqxbige bmizzzpgfp (nfmgvopbuk ) | Negative | 22 Sep 2019 | |||
Placebo | glnivaenif(sswvzhwvzq) = raavixvijj bmizzzpgfp (nfmgvopbuk ) | ||||||
Phase 2 | 352 | Placebo (Placebo) | bwvivhhcem(wommindkzx) = ukakzpgpol kifeuqvusr (wslobaamvi, 8.00) View more | - | 19 Jun 2019 | ||
Placebo+Laquinimod (Laquinimod 0.5 mg) | bwvivhhcem(wommindkzx) = lhtpkypsda kifeuqvusr (wslobaamvi, 8.34) View more | ||||||
Phase 2 | - | abdyveefjd(dljbvwqthu): P-Value = 0.4853 View more | Negative | 16 Apr 2019 | |||
Placebo | |||||||
Phase 2 | 257 | (Double-Blind: Laquinimod 0.3 mg) | qusfkbzves = odveafgdah rwgtcxvnca (ytoqktwatn, dknivyopca - gypmqtampj) View more | - | 27 Mar 2019 | ||
(Double-Blind: Laquinimod 0.6 mg) | qusfkbzves = rqlztwyqxj rwgtcxvnca (ytoqktwatn, eueinjggbe - tklyxijkby) View more |